EU Public Consultations Relevant to Our Community
Three important European consultations are currently open for feedback. These initiatives represent key opportunities to help shape policy and regulatory frameworks impacting research, innovation, and healthcare across Europe.
The European Commission has recently launched three public consultations of relevance to the in silico medicine community, which we would like to bring to your attention.
We strongly encourage the members of our community to actively engage in these consultations. Your expertise and insights are essential in ensuring that the perspectives of our field are well represented. The VPH Society is happy to collaborate in synergy to coordinate contributions and strengthen our collective voice.
If you’re interested in collaborating, please contact us no later than 18 May 2026.
By contributing together, we can help shape policies that better reflect the needs and potential of our community.
——————
Cardiovascular Health
Feedback period: 21 April 2026 – 19 May 2026
The proposed recommendations will help Member States organise evidence-based screening for cardiovascular diseases tailored to their specific health systems and national and regional situations. The aim is to improve early detection and diagnosis of cardiovascular diseases and key risk factors, thereby reducing premature mortality from these and related non-communicable diseases – while also reducing health inequalities within and between Member States.
——————
Medical Devices and In Vitro Diagnostics – Targeted Revision of EU Rules
Feedback deadline: 19 June 2026 –> new deadline: 06 July 2026
This initiative seeks to simplify EU rules for medical devices and in vitro diagnostics. It aims to ensure availability of safe and innovative devices to safeguard a high level of patient safety, public health and healthcare.
Drawing on an evaluation of the current rules, the initiative seeks to:
- make the EU medical device sector more competitive in the internal market and globally, to support innovation and reduce dependencies;
- make safety requirements more cost-efficient and proportionate.
——————
Biotech Act
Feedback period: 19 December 2025 – 19 June 2026 –> new deadline: 06 July 2026
The biotech sector plays a critical role in several areas of the EU economy. It is research-driven, fast-moving and requires substantial public and private investments.
The Biotech Act will propose a series of measures to create an enabling environment to accelerate the transition of biotech products from laboratory to factory and to the market, while maintaining the highest safety standards for the protection of the population and the environment.
